Phase I trial of intravenous attenuated vaccinia virus (GL-ONC1) with concurrent chemoradiotherapy (CRT) for locoregionally advanced head and neck carcinoma.

Mell, Loren K.; Yu, Yong A.; Brumund, Kevin T.; Daniels, Gregory A.; Advani, Sunil J.; Weisman, Robert A.; Sanghvi, Parag; Martin, Peter; Wright, Mary E.; Onyeama, Sara-Jane N; Zhang, Qian; Pôld, Anu; Chamberlin, Terry; Frentzen, Alexa; Szalay, Aladar A.

doi:10.1200/jco.2015.33.15_suppl.6026

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GL-ONC1 (GLV-1h68), a luciferase-expressing TK-inactivated vaccinia virus, has been tested in several different tumor models [ 39 , 140 , 141 , 142 ]. Preliminary results from two Phase I trials have been reported, one using GL-ONC1 as a standalone treatment for patients with malignant pleural effusions and the other using GL-ONC1 in combination with chemoradiation for head and neck cancer [ 143 , 144 ]. A Phase I trial using this OV for advanced peritoneal carcinomatosis has also been completed (NCT01443260).…”

Section: Clinical Trialsmentioning

confidence: 99%

From Benchtop to Bedside: A Review of Oncolytic Virotherapy

et al. 2016

View full text Add to dashboard Cite

Oncolytic viruses (OVs) demonstrate the ability to replicate selectively in cancer cells, resulting in antitumor effects by a variety of mechanisms, including direct cell lysis and indirect cell death through immune-mediate host responses. Although the mechanisms of action of OVs are still not fully understood, major advances have been made in our understanding of how OVs function and interact with the host immune system, resulting in the recent FDA approval of the first OV for cancer therapy in the USA. This review provides an overview of the history of OVs, their selectivity for cancer cells, and their multifaceted mechanism of antitumor action, as well as strategies employed to augment selectivity and efficacy of OVs. OVs in combination with standard cancer therapies are also discussed, as well as a review of ongoing human clinical trials.

show abstract